Preclinical data for CLYM116, anti-APRIL monoclonal antibody, highlight favorable pharmacokinetic and pharmacodynamic profile ...

U.S. biotech firm Nabla Bio said on Tuesday it has signed a second major research partnership with Japanese drugmaker Takeda ...

Nabla Bio has entered a new multi-year research collaboration with Takeda to advance AI-driven design of protein therapeutics ...

Nabla Bio partners with Takeda to use its AI platform JAM for designing antibodies, receiving upfront payments and potential ...

PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) presented initial data from its ongoing RESET-PV™ trial evaluating rese ...

Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today announced that it will present new clinical data from its Phase 2 trial of EB613 at ...

PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn’s disease (FSCD) and ulcerative colitis (UC) to address significant unmet medical ...

Amid an increasing focus by the design community, end users and consumers, more suppliers are bringing PVC-free resilient ...

CN Bio, a leading provider of benchtop Organ-on-a-chip (OOC) solutions that accelerate drug discovery and development, today announced the launch of PhysioMimix® Core.

Patent number 3,174,137, which is titled Gut Microbiota Bioactivated PDE4 Inhibitor Precursors, encompasses the composition ...

Early testing suggests that applying structured data extends your visibility and stability in an AI-generated snippet.